About M Sea Pharmaceuticals
M Sea Pharmaceuticals is an Industrial Goods & Manufacturing company. Manufacturing of pharmaceutical formulations and related services in India. It operates in the Industrial Goods & Manufacturing and Healthcare sectors. Its Indian entity M Sea Pharmaceuticals Private Limited reported revenue of βΉ13.67 Cr. M Sea Pharmaceuticals offers products and services including Capsules and Dry Syrup. Its focus areas include Contract Manufacturing, Third Party Services, Outsourcing and Pharmaceuticals.
Company details
M Sea Pharmaceuticals Pvt. Ltd. is recognized as a pharmaceutical manufacturer based in India, certified with ISO 9001-2015, GLP, and WHO GMP standards. It is engaged in producing formulations such as tablets, capsules, dry syrups, and oral liquids, with facilities designed to comply with international manufacturing norms. A commitment to quality and safety is upheld, ensuring formulations meet regulatory guidelines. Services include contract and third-party manufacturing for Beta Lactum products, supporting business alliances in the sector. This approach is maintained to deliver reliable therapeutic options.
- SectorsIndustrial Goods & ManufacturingHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website mseapharma.com
- Legal Name M Sea Pharmaceuticals Pvt. Ltd
- Date of Incorporation 01 Apr, 2015
- Jurisdiction Himachal Pradesh, India
- Indian entity revenue₹13.67 Cr
FY 2024 · -3% YoY
- Indian entity net profit₹17.8 Lakh
FY 2024 · 1% margin
- Indian entity EBITDA₹1.18 Cr
FY 2024 · 9% margin
Associated legal entities of M Sea Pharmaceuticals
M Sea Pharmaceuticals operates through M Sea Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| M Sea Pharmaceuticals Private Limited CIN U74900HP2015PTC000911 | Active | 01 Apr 2015 | Paonta Sahib, Himachal Pradesh | ₹13.7 Cr | 43 | 6 | View details |
Products & Services of M Sea Pharmaceuticals
M Sea Pharmaceuticals offers a comprehensive portfolio of products and services, including Capsules and Dry Syrup.
Capsules are produced for both Beta Lactum and non-Beta Lactum uses as part of the pharmaceutical formulations offered.
Dry syrup formulations are manufactured for Beta Lactum products to ensure they meet required therapeutic standards.
Board of directors of M Sea Pharmaceuticals Private Limited (M Sea Pharmaceuticals)
M Sea Pharmaceuticals Private Limited is the primary company behind M Sea Pharmaceuticals. The board of M Sea Pharmaceuticals Private Limited currently have 6 directors; the longest-serving is Krishnamoorthy Chandru, appointed in 2015. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Krishnamoorthy Chandru DIN 00893481 | Director | 01 Apr 2015 | 11 yrs 7 mo | M Sea Pharmaceuticals Private Limited |
| Selvaraj Santha Kumar DIN 01494954 | Director | 19 Nov 2015 | 10 yrs 11 mo | M Sea Pharmaceuticals Private Limited |
| Harinath Harinath DIN 01514762 | Director | 19 Nov 2015 | 10 yrs 11 mo | M Sea Pharmaceuticals Private Limited |
| Shailender Kumar DIN 07595696 | Director | 31 Mar 2017 | 9 yrs 7 mo | M Sea Pharmaceuticals Private Limited |
| Ajay Agarwal DIN 00728582 | Director | 22 Feb 2018 | 8 yrs 8 mo | M Sea Pharmaceuticals Private Limited |
| Manish Agarwal DIN 08279133 | Director | 13 Nov 2018 | 8 yrs | M Sea Pharmaceuticals Private Limited |
Financials of M Sea Pharmaceuticals
Figures of M Sea Pharmaceuticals Private Limited, the primary company behind M Sea Pharmaceuticals, for FY 2024. Revenue was ₹13.67 Cr (-3% year on year). Net profit was ₹17.8 Lakh (1% margin). EBITDA was ₹1.18 Cr (9% margin). Revenue has grown at a compounded annual rate of +8% over three years and +12% over five years.
- ₹13.67 CrRevenue · FY 2024 · -3% YoY
- ₹17.8 LakhNet profit · 1% margin
- ₹1.18 CrEBITDA · 9% margin
- ₹1.97 CrPaid-up capital
- 43Employees (provident fund records)
- +8%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of M Sea Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for M Sea Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about M Sea Pharmaceuticals
The primary company behind M Sea Pharmaceuticals, M Sea Pharmaceuticals Private Limited, reported revenue of βΉ13.67 Cr for FY 2024, down 3% year on year.
M Sea Pharmaceuticals Pvt. Ltd. is recognized as a pharmaceutical manufacturer based in India, certified with ISO 9001-2015, GLP, and WHO GMP standards. It is engaged in producing formulations such as tablets, capsules, dry syrups, and oral liquids, with facilities designed to comply with international manufacturing norms. A commitment to quality and safety is upheld, ensuring formulations meet regulatory guidelines. Services include contract and third-party manufacturing for Beta Lactum products, supporting business alliances in the sector. This approach is maintained to deliver reliable therapeutic options.
M Sea Pharmaceuticals offers Capsules and Dry Syrup.
M Sea Pharmaceuticals operates through M Sea Pharmaceuticals Private Limited.
The legal entities of M Sea Pharmaceuticals currently have 6 directors, including Manish Agarwal, Shailender Kumar, Selvaraj Santha Kumar and others.
